Abbasinazari 2015.

Study characteristics
Methods	Double‐blind, randomised, placebo‐controlled trial
Participants	Diagnosis: DSM‐IV major depressive episode N: 40 Age: memantine 5 mg/day group M = 36.5 (SD = 12.0); placebo group M = 41.6 (SD = 11.2) Sex: memantine 5 mg/day group 65% female; placebo group 50% female Baseline depression severity: not reported.
Interventions	Given 5 mg/day of memantine or placebo beginning the day before the first session of ECT until the fourth session of ECT Memantine 5 mg/day (N = 20) Placebo (N = 20) Concomitant treatment :not stated
Outcomes	Modified Mental State Examination (MMSE)
Notes	Not included in analysis due to study not using depression rating scales (assessed cognition scores only)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A sequence was computer‐generated to randomly assign patients to two groups in a 1:1 ratio. This sequence was generated in blocks of 4, 8 and 12 using the 'blockrand' extension of the R Project software package."
Allocation concealment (selection bias)	Low risk	Quote: "Knowledge of this sequence was available only to a nurse not involved in volunteer recruitment. This nurse allocated patients to either the placebo group or the memantine group by flipping a coin."
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Study described as double‐blind. Quote: "A strategy of numbered boxes was used for sequence concealment".
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Study described as double‐blind. Quote: "A strategy of numbered boxes was used for sequence concealment".
Incomplete outcome data (attrition bias) All outcomes	Low risk	Study reports dropouts (zero)
Selective reporting (reporting bias)	Unclear risk	Protocol unavailable. Average HAM‐D scores are missing
Other bias	Low risk	No other potential sources of bias identified